Evaxion Biotech to Present Upcoming Financial Insights
Evaxion Biotech A/S (NASDAQ: EVAX) is gearing up to announce significant developments in its business and financial performance for the third quarter of 2024. This innovative company, a leader in the clinical-stage TechBio sector, is especially known for its pioneering AI-Immunology™ powered vaccine technology.
Details of the Event
The anticipated business update and financial results will be shared on a scheduled conference call and webcast on the 31st of October. The presentation will kick off at 13:30 CET/08:30 EST, offering participants a comprehensive breakdown of their latest achievements and progress. This session is not just an informative session; it is designed to engage with the audience, allowing for a Q&A segment to clarify any inquiries regarding their innovative technology and future plans.
How to Access the Conference Call
Individuals interested in participating are encouraged to register in advance. This registration will grant access to the dial-in numbers and a unique PIN code required for joining the call. Attendees should dial in at least fifteen minutes early to ensure a smooth connection.
Webcast Participation
For those who prefer to watch the event online, a dedicated webcast will also be available, mirroring the insights shared during the conference. A recording of the webcast will be accessible shortly after the event, allowing interested parties to catch up on the details as needed.
Contact Information
Evaxion Biotech is committed to maintaining open lines of communication with its stakeholders. Mads Kronborg, Vice President for Investor Relations & Communication, can be reached for any inquiries. His contact number is +45 53 54 82 96, and stakeholders can also reach out via email if they have questions that require further discussion.
About Evaxion Biotech A/S
At the front of innovation in TechBio, Evaxion Biotech leverages its advanced AI-Immunology™ platform to revolutionize immunotherapy. The company excels in developing personalized vaccines and immunotherapies for a range of health conditions, including cancer and infectious diseases.
Innovative Approach to Immunology
By employing scalable AI prediction models, Evaxion decodes complex aspects of the human immune system, which leads to the formulation of targeted treatments where there previously were few options. Their oncology pipeline brims with potential, and the preclinical studies into bacterial and viral diseases present a promising outlook for high-demand medical needs.
Commitment to Transform Lives
Evaxion's commitment to harnessing AI technology is more than just a market strategy. It reflects a deep-rooted mission to transform patient experiences and improve treatment outcomes globally. The future of healthcare lies in these kinds of breakthroughs, and Evaxion is at the forefront.
Frequently Asked Questions
What is the date for Evaxion's financial results announcement?
Evaxion Biotech is scheduled to announce its financial results for the third quarter on October 31, 2024.
When will the conference call occur?
The conference call will take place at 13:30 CET/08:30 EST on the same day as the financial announcement.
How can I access the conference call?
Interested individuals should register beforehand to receive the necessary dial-in information and unique PIN.
Will there be a recording of the event?
Yes, the webcast will be recorded and made available shortly after the event for those who cannot attend live.
Who can I contact for more information?
You can reach out to Mads Kronborg, Vice President of Investor Relations & Communication, at the contact number provided in the announcement.
